Light Clinical Trials

43 recruitingLast updated: July 25, 2026

There are 43 actively recruiting light clinical trials across 21 countries. Studies span Not Applicable, Phase 2, Phase 1, Early Phase 1, Phase 3. Top locations include Boston, Massachusetts, United States, Beijing, Beijing Municipality, China, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Light Trials at a Glance

43 actively recruiting trials for light are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Not Applicable with 17 trials, with the heaviest enrollment activity in Boston, Beijing, and New York. Lead sponsors running light studies include Beijing Boren Hospital, Institute of Hematology & Blood Diseases Hospital, China, and Nanjing University School of Medicine.

Browse light trials by phase

Treatments under study

About Light Clinical Trials

Looking for clinical trials for Light? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Light trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Light clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 43 trials

Recruiting
Phase 2

Teclistamab-Daratumumab in AL Amyloidosis

Amyloid Light-chain Amyloidosis
Rajshekhar Chakraborty, MD25 enrolled3 locationsNCT07110844
Recruiting
Not Applicable

Efficacy of Bright Light Therapy on Cognitive Impairment in Major Depressive Disorder and Its Neuroimaging Mechanisms: Protocol for a Randomised Controlled Trial

Cognitive ImpairmentMajor Depressive Disorder (MDD)Neuroimaging+1 more
Peking University Sixth Hospital120 enrolled2 locationsNCT07508215
Recruiting
Phase 1

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

AmyloidosisLight Chain AmyloidosisRelapsed AL Amyloidosis+1 more
Alexion Pharmaceuticals, Inc.91 enrolled18 locationsNCT07081646
Recruiting
Phase 2

CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment

Multiple Myeloma (MM)Multiple Myeloma Light Chain Induced Renal Insufficiency
Institute of Hematology & Blood Diseases Hospital, China26 enrolled1 locationNCT07585760
Recruiting
Phase 1Phase 2

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Relapsed/Refractory Systemic Light Chain Amyloidosis
Regeneron Pharmaceuticals220 enrolled20 locationsNCT06292780
Recruiting
Not Applicable

Early DHA/ARA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial

PrematureInfant MalnutritionLight-For-Dates With Signs of Fetal Malnutrition+1 more
University of Alabama at Birmingham152 enrolled1 locationNCT06207071
Recruiting
Not Applicable

Assessing the Efficacy of Photodynamic Therapy for Preventing Surgical Site Infections

SurgeryLight; Therapy, ComplicationsNasal Disease
Guy's and St Thomas' NHS Foundation Trust80 enrolled1 locationNCT06731881
Recruiting

Hospital Environmental Exposure

Air qualitySleepNoise exposure+2 more
University of Leicester120 enrolled1 locationNCT06802367
Recruiting
Early Phase 1

Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis

AL AmyloidosisSystemic Light Chain AmyloidosisRelapsed/Refractory Light Chain Amyloidosis
Beijing Boren Hospital30 enrolled1 locationNCT07626476
Recruiting
Not Applicable

Light and Anesthesia

AnesthesiaSedationLight
Peking University People's Hospital66 enrolled1 locationNCT07517484
Recruiting
Not Applicable

Polarized Light Therapy for Radiation Dermatitis in Breast Cancer

Breast Cancer SurvivorsRadio DermatitisPolarized Light
Beni-Suef University60 enrolled1 locationNCT07600957
Recruiting
Not Applicable

Feasibility of Light Therapy in the Pediatric Intensive Care Unit (ICU)

Circadian DysregulationLight ExposurePediatric Critical Illness
Laura Beth Kalvas30 enrolled1 locationNCT07384585
Recruiting
Phase 1Phase 2

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Immunoglobulin Light Chain (AL) Amyloidosis
AbbVie76 enrolled23 locationsNCT06158854
Recruiting
Phase 1Phase 2

Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

Systemic Light Chain Amyloidosis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.70 enrolled27 locationsNCT07266116
Recruiting
Not Applicable

Peripheral Blood Flow Responses to Electromagnetic Energy

Exposure to Man-made Visible Light
University of Alabama at Birmingham40 enrolled1 locationNCT02370199
Recruiting
Not Applicable

Blue Light for Donor Site Healing in Burn Patients

Donor Site ComplicationBurnPhotobiomodulation Therapy+1 more
AUSL Romagna Rimini25 enrolled1 locationNCT07453927
Recruiting
Phase 2

BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis

Systemic Light Chain Amyloidosis
Institute of Hematology & Blood Diseases Hospital, China21 enrolled1 locationNCT07151690
Recruiting
Not Applicable

Nighttime Synchrony of Your Nutrition and Circadian Health

Circadian misalignmentSleepCircadian Rhythm+8 more
University of Utah120 enrolled1 locationNCT07329283
Recruiting
Not Applicable

Light in Frail Elderly - the Effect of a Dynamic Light for Sleep and Circadian Rhythm

SleepFatigueHumans+9 more
Region Skane300 enrolled1 locationNCT05107947